Identification

Name
Procarbazine
Accession Number
DB01168  (APRD00695)
Type
Small Molecule
Groups
Approved
Description

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Structure
Thumb
Synonyms
  • 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
  • 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
  • 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
  • N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
  • N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
  • N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
  • N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
  • N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
  • p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
  • Procarbazin
  • Procarbazina
  • Procarbazinum
External IDs
RO-4-6467
Product Ingredients
IngredientUNIICASInChI Key
Procarbazine hydrochlorideXH0NPH5ZX8366-70-1OCSSHHHAHMCFDV-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MatulaneCapsule50 mg/1OralSigma Tau Pharmaceuticals, Inc.1985-12-27Not applicableUs
MatulaneCapsule50 mgOralLeadiant Biosciences, Inc1970-12-31Not applicableCanada
International/Other Brands
Indicarb / Natulan
Categories
UNII
35S93Y190K
CAS number
671-16-9
Weight
Average: 221.2988
Monoisotopic: 221.152812245
Chemical Formula
C12H19N3O
InChI Key
CPTBDICYNRMXFX-UHFFFAOYSA-N
InChI
InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
IUPAC Name
4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide
SMILES
CNNCC1=CC=C(C=C1)C(=O)NC(C)C

Pharmacology

Indication

For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.

Structured Indications
Pharmacodynamics

Procarbazine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Procarbazine is cell-phase specific for the S phase of cell division.

Mechanism of action

The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
AMonoamine oxidase
inhibitor
Human
Absorption

Procarbazine is rapidly and completely absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Procarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine.

Route of elimination
Not Available
Half life

10 minutes

Clearance
Not Available
Toxicity

LD50=785 mg/kg (orally in rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Procarbazine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Procarbazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Procarbazine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Procarbazine.Experimental
AcarboseProcarbazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololProcarbazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Acetophenazine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Procarbazine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Procarbazine.Experimental
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Procarbazine.Experimental
AlbiglutideProcarbazine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Procarbazine.Approved, Illicit
AliskirenProcarbazine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Procarbazine.Approved, Investigational
AlogliptinProcarbazine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Procarbazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Procarbazine.Illicit
AlprenololProcarbazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Procarbazine.Approved
AmbrisentanProcarbazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineProcarbazine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Procarbazine.Approved
AmlodipineProcarbazine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Procarbazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Procarbazine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Procarbazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Asenapine.Approved
AtenololProcarbazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineProcarbazine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineProcarbazine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Azaperone.Investigational, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bambuterol.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Procarbazine.Investigational
BenazeprilProcarbazine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideProcarbazine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinProcarbazine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Benperidol.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Procarbazine.Approved, Illicit
BepridilProcarbazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Procarbazine.Approved
BetaxololProcarbazine may increase the hypotensive activities of Betaxolol.Approved
BethanidineProcarbazine may increase the hypotensive activities of Bethanidine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Procarbazine.Approved, Investigational
BezafibrateThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bezafibrate.Approved
BietaserpineProcarbazine may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bifeprunox.Investigational
BimatoprostProcarbazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololProcarbazine may increase the hypotensive activities of Bisoprolol.Approved
BosentanProcarbazine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Procarbazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumProcarbazine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Procarbazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Procarbazine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bromperidol.Investigational
BupranololProcarbazine may increase the hypotensive activities of Bupranolol.Approved
BupropionProcarbazine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Procarbazine.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Procarbazine.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Procarbazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Procarbazine.Approved
CadralazineProcarbazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineProcarbazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinProcarbazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanProcarbazine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilProcarbazine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilProcarbazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilProcarbazine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Procarbazine.Approved, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Carbocisteine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Procarbazine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Cariprazine.Approved
CaroxazoneProcarbazine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololProcarbazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolProcarbazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololProcarbazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideProcarbazine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Procarbazine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideProcarbazine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneProcarbazine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineProcarbazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilProcarbazine may increase the hypotensive activities of Cilazapril.Approved
CirazolineProcarbazine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Procarbazine.Approved
ClemastineProcarbazine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clomipramine.Approved, Vet Approved
ClonidineProcarbazine may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clopenthixol.Experimental
CloranololProcarbazine may increase the hypotensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Procarbazine.Approved
ClothiapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Procarbazine.Approved, Illicit
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Procarbazine.Approved
CryptenamineProcarbazine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Procarbazine.Approved
CyclopenthiazideProcarbazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Procarbazine.Approved, Investigational
CyclothiazideProcarbazine may increase the hypotensive activities of Cyclothiazide.Approved
CymarinCymarin may decrease the cardiotoxic activities of Procarbazine.Experimental
CyproheptadineProcarbazine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinProcarbazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Procarbazine.Investigational
DebrisoquinProcarbazine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilProcarbazine may increase the hypotensive activities of Delapril.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine.Approved
DeserpidineProcarbazine may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Procarbazine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Procarbazine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Desvenlafaxine.Approved
DexmethylphenidateProcarbazine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Procarbazine.Approved, Illicit
DextromethorphanProcarbazine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Procarbazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procarbazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Procarbazine.Approved, Investigational
DiazoxideProcarbazine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinProcarbazine may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineProcarbazine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionProcarbazine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Procarbazine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Procarbazine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Procarbazine.Approved
DihydralazineProcarbazine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Procarbazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Procarbazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Procarbazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Procarbazine.Experimental, Illicit
DiltiazemProcarbazine may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Procarbazine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dipivefrin.Approved
DisopyramideProcarbazine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Procarbazine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideProcarbazine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinProcarbazine may increase the serotonergic activities of Dosulepin.Approved
DoxapramProcarbazine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinProcarbazine may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Procarbazine.Approved
DoxylamineProcarbazine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Procarbazine.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Procarbazine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droxidopa.Approved, Investigational
DulaglutideProcarbazine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Procarbazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Procarbazine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ecopipam.Investigational
EfonidipineProcarbazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Procarbazine.Approved, Investigational
EmpagliflozinProcarbazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilProcarbazine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatProcarbazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineProcarbazine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Procarbazine.Approved, Investigational
EpanololProcarbazine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolProcarbazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanProcarbazine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Procarbazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Procarbazine is combined with Escitalopram.Approved, Investigational
EsmirtazapineProcarbazine may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Procarbazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Procarbazine.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Procarbazine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Procarbazine.Illicit, Vet Approved
ExenatideProcarbazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineProcarbazine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamProcarbazine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Procarbazine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidProcarbazine may increase the hypotensive activities of Ferulic acid.Experimental
FingolimodProcarbazine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluanisone.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Procarbazine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procarbazine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Formoterol.Approved, Investigational
FosinoprilProcarbazine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Procarbazine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Procarbazine.Approved, Investigational, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Procarbazine.Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Procarbazine.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Procarbazine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Procarbazine.Experimental
GliclazideProcarbazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideProcarbazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideProcarbazine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideProcarbazine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Procarbazine.Approved, Investigational
GuanabenzProcarbazine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelProcarbazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineProcarbazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineProcarbazine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineProcarbazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorProcarbazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzProcarbazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanProcarbazine may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.Approved
HarmalineHarmaline may increase the hypertensive activities of Procarbazine.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Procarbazine.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Procarbazine.Approved, Withdrawn
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Procarbazine.Approved, Illicit, Investigational
HexamethoniumProcarbazine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineProcarbazine may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineProcarbazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideProcarbazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideProcarbazine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Procarbazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Iloperidone.Approved
ImidaprilProcarbazine may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Procarbazine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Procarbazine.Investigational, Withdrawn
IndapamideProcarbazine may increase the hypotensive activities of Indapamide.Approved
IndenololProcarbazine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminProcarbazine may increase the hypotensive activities of Indoramin.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Procarbazine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Procarbazine.Investigational
Insulin AspartProcarbazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirProcarbazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineProcarbazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineProcarbazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanProcarbazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproProcarbazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Procarbazine.Approved
IprindoleProcarbazine may increase the serotonergic activities of Iprindole.Experimental
IproclozideProcarbazine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Procarbazine.Withdrawn
IrbesartanProcarbazine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline.Approved
IsradipineProcarbazine may increase the hypotensive activities of Isradipine.Approved
KetanserinProcarbazine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Procarbazine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Procarbazine.Approved, Nutraceutical, Withdrawn
LabetalolProcarbazine may increase the hypotensive activities of Labetalol.Approved
LacidipineProcarbazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Procarbazine.Experimental
LatanoprostProcarbazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Leflunomide.Approved, Investigational
LercanidipineProcarbazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Procarbazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Procarbazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Procarbazine is combined with Levomilnacipran.Approved
LevonordefrinProcarbazine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Procarbazine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Procarbazine is combined with Linezolid.Approved, Investigational
LinsidomineProcarbazine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideProcarbazine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procarbazine.Approved, Investigational
LisinoprilProcarbazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Procarbazine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Procarbazine.Illicit
LofepramineProcarbazine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineProcarbazine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lorcaserin.Approved
LosartanProcarbazine may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.Approved
MacitentanProcarbazine may increase the hypotensive activities of Macitentan.Approved
ManidipineProcarbazine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Procarbazine.Approved
MebanazineProcarbazine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineProcarbazine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminProcarbazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Melperone.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Procarbazine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Procarbazine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Procarbazine.Experimental
MequitazineProcarbazine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Mesoridazine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Procarbazine.Investigational, Withdrawn
MetaraminolProcarbazine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminProcarbazine may increase the hypoglycemic activities of Metformin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Procarbazine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Procarbazine.Approved, Illicit
MethoserpidineProcarbazine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methotrimeprazine.Approved
MethoxamineProcarbazine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Procarbazine.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Procarbazine.Experimental
Methylene blueProcarbazine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateProcarbazine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Procarbazine.Experimental
MetipranololProcarbazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.Approved, Investigational
MetolazoneProcarbazine may increase the hypotensive activities of Metolazone.Approved
MetoprololProcarbazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineProcarbazine may increase the hypotensive activities of Metyrosine.Approved
MianserinProcarbazine may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilProcarbazine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineProcarbazine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Procarbazine.Experimental, Illicit, Investigational
MifepristoneProcarbazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolProcarbazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Procarbazine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Procarbazine.Approved
MinoxidilProcarbazine may increase the hypotensive activities of Minoxidil.Approved
MirtazapineProcarbazine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Procarbazine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Moclobemide.Approved
MoexiprilProcarbazine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Mosapramine.Experimental
MoxonidineProcarbazine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineProcarbazine may increase the hypotensive activities of Muzolimine.Experimental
NadololProcarbazine may increase the hypotensive activities of Nadolol.Approved
NaftopidilProcarbazine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Procarbazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Procarbazine.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.Approved, Investigational
NateglinideProcarbazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololProcarbazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Procarbazine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Procarbazine.Withdrawn
NicardipineProcarbazine may increase the hypotensive activities of Nicardipine.Approved
NicorandilProcarbazine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineProcarbazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineProcarbazine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineProcarbazine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineProcarbazine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineProcarbazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideProcarbazine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineProcarbazine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Procarbazine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Procarbazine.Approved
OctamoxinProcarbazine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Procarbazine.Experimental, Investigational
OlmesartanProcarbazine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olodaterol.Approved
OmapatrilatProcarbazine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Procarbazine.Approved
OpipramolProcarbazine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Procarbazine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Procarbazine.Approved
OxprenololProcarbazine may increase the hypotensive activities of Oxprenolol.Approved
OxypertineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Procarbazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Procarbazine.Approved, Investigational
PargylineProcarbazine may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Procarbazine.Approved, Investigational
PenbutololProcarbazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Penfluridol.Experimental
PentamidineProcarbazine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Procarbazine.Approved, Vet Approved
PentoliniumProcarbazine may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Procarbazine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilProcarbazine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perphenazine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Procarbazine.Experimental
PethidineProcarbazine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Procarbazine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Procarbazine.Approved
PheniprazineProcarbazine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Procarbazine.Experimental
PhenoxybenzamineProcarbazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineProcarbazine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Procarbazine.Approved, Illicit
PhentolamineProcarbazine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineProcarbazine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Procarbazine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Procarbazine.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Procarbazine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pimozide.Approved
PinacidilProcarbazine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololProcarbazine may increase the hypotensive activities of Pindolol.Approved
PioglitazoneProcarbazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Procarbazine.Investigational
PirlindolePirlindole may increase the hypertensive activities of Procarbazine.Approved
PivhydrazineProcarbazine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenProcarbazine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorProcarbazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideProcarbazine may increase the hypotensive activities of Polythiazide.Approved
PramlintideProcarbazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinProcarbazine may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Procarbazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Propericiazine.Approved
PropranololProcarbazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Procarbazine.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procarbazine.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Procarbazine.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Procarbazine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Quetiapine.Approved
QuinaprilProcarbazine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineProcarbazine may increase the hypoglycemic activities of Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Procarbazine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Raclopride.Investigational
RamiprilProcarbazine may increase the hypotensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Procarbazine.Approved
RemikirenProcarbazine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride.Approved, Withdrawn
RepaglinideProcarbazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineProcarbazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Reserpine.Approved, Investigational
RilmenidineProcarbazine may increase the hypotensive activities of Rilmenidine.Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Procarbazine.Investigational
RiociguatProcarbazine may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ritanserin.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Procarbazine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Procarbazine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Procarbazine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Procarbazine.Approved, Investigational
RosiglitazoneProcarbazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Procarbazine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Procarbazine.Approved
SafrazineProcarbazine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Salmeterol.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Procarbazine.Approved
SaprisartanProcarbazine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinProcarbazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Procarbazine.Approved, Investigational, Vet Approved
SelexipagProcarbazine may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Procarbazine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Procarbazine.Approved
SitagliptinProcarbazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanProcarbazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilProcarbazine may increase the hypotensive activities of Spirapril.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Procarbazine.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine.Approved, Investigational
SulfadiazineProcarbazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleProcarbazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleProcarbazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Procarbazine.Approved, Investigational
SunitinibProcarbazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Procarbazine.Approved, Investigational
TalinololProcarbazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Procarbazine.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Procarbazine.Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Procarbazine.Approved
TelmisartanProcarbazine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilProcarbazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Terbutaline.Approved
TerlipressinProcarbazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Procarbazine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Procarbazine.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tetrahydropalmatine.Investigational
TetryzolineProcarbazine may increase the hypertensive activities of Tetryzoline.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Procarbazine.Investigational
TheodrenalineProcarbazine may increase the hypotensive activities of Theodrenaline.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Procarbazine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tiapride.Approved, Investigational
TiboloneProcarbazine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenProcarbazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Procarbazine.Experimental
TimololProcarbazine may increase the hypotensive activities of Timolol.Approved
TofacitinibProcarbazine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideProcarbazine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineProcarbazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideProcarbazine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Procarbazine.Approved, Withdrawn
TolonidineProcarbazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Procarbazine.Approved
TorasemideProcarbazine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Procarbazine.Approved, Investigational
TrandolaprilProcarbazine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Procarbazine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Procarbazine.Approved, Investigational
TravoprostProcarbazine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Procarbazine.Approved, Investigational
TreprostinilProcarbazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideProcarbazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinProcarbazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanProcarbazine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Procarbazine.Approved
TropisetronTropisetron may increase the serotonergic activities of Procarbazine.Approved, Investigational
UnoprostoneProcarbazine may increase the hypotensive activities of Unoprostone.Approved
UrapidilProcarbazine may increase the hypotensive activities of Urapidil.Investigational
ValsartanProcarbazine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Procarbazine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Procarbazine is combined with Veralipride.Experimental
VilanterolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Procarbazine.Approved
VincamineProcarbazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineProcarbazine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Procarbazine.Approved
XipamideProcarbazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineProcarbazine may increase the hypotensive activities of Xylometazoline.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Procarbazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Procarbazine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.Approved
ZofenoprilProcarbazine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Procarbazine.Approved, Investigational
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Procarbazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US3520926
General References
Not Available
External Links
Human Metabolome Database
HMDB15299
KEGG Drug
D08423
KEGG Compound
C07402
PubChem Compound
4915
PubChem Substance
46507706
ChemSpider
4746
ChEBI
71417
ChEMBL
CHEMBL1321
Therapeutic Targets Database
DAP000986
PharmGKB
PA451112
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Procarbazine
ATC Codes
L01XB01 — Procarbazine
MSDS
Download (63.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Neurotoxicity1
1CompletedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
2Active Not RecruitingTreatmentChemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Malignant Lymphomas / Neurotoxicity / Radiation Toxicity1
2Active Not RecruitingTreatmentLymphoma, Hodgkins2
2Active Not RecruitingTreatmentMalignant Lymphomas2
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2CompletedTreatmentBrain and Central Nervous System Tumors4
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentMalignant Lymphomas6
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentLymphoma, Hodgkins1
2SuspendedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentNewly Diagnosed Non Methylated Glioblastoma Multiforme Grade 41
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentPrimary Non Hodgkin Lymphoma of the Central Nervous System1
2Unknown StatusTreatmentRecurrent Glioblastoma Multiforme1
2WithdrawnTreatmentMalignant Lymphomas1
2, 3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3Active Not RecruitingTreatmentMalignant Lymphomas4
3CompletedTreatmentBrain and Central Nervous System Tumors4
3CompletedTreatmentLymphoma, Hodgkins3
3CompletedTreatmentMalignant Lymphomas2
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3RecruitingTreatmentBrain and Central Nervous System Tumors1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors1
3Unknown StatusTreatmentMalignant Lymphomas1
3WithdrawnTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentMalignant Lymphomas1
Not AvailableNot Yet RecruitingTreatmentAdvanced Hodgkin's Lymphoma1
Not AvailableNot Yet RecruitingTreatmentRecurrent High-grade Glioma1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral50 mg/1
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Matulane 50 mg capsule55.68USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)223 °CNot Available
water solubility1420 mg/LNot Available
logP0.06HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.228 mg/mLALOGPS
logP0.53ALOGPS
logP0.99ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)15.03ChemAxon
pKa (Strongest Basic)5.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area53.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity86.98 m3·mol-1ChemAxon
Polarizability25.88 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9855
Caco-2 permeable+0.6013
P-glycoprotein substrateNon-substrate0.5748
P-glycoprotein inhibitor INon-inhibitor0.8839
P-glycoprotein inhibitor IINon-inhibitor0.9771
Renal organic cation transporterNon-inhibitor0.7974
CYP450 2C9 substrateNon-substrate0.8293
CYP450 2D6 substrateNon-substrate0.702
CYP450 3A4 substrateNon-substrate0.5484
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9414
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.6428
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity2.4348 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9785
hERG inhibition (predictor II)Non-inhibitor0.9287
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-016u-6900000000-6488b097a4640e8af61a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0096-0910000000-161c214dc9eb9c75895b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzamides
Alternative Parents
Benzoyl derivatives / Secondary carboxylic acid amides / Alkylhydrazines / Organopnictogen compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Benzamide / Benzoyl / Secondary carboxylic acid amide / Carboxamide group / Alkylhydrazine / Carboxylic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
benzamides, hydrazines (CHEBI:71417)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Ogawa K, Hiraku Y, Oikawa S, Murata M, Sugimura Y, Kawamura J, Kawanishi S: Molecular mechanisms of DNA damage induced by procarbazine in the presence of Cu(II). Mutat Res. 2003 Aug 5;539(1-2):145-55. [PubMed:12948823]
  4. Kyrtopoulos SA, Anderson LM, Chhabra SK, Souliotis VL, Pletsa V, Valavanis C, Georgiadis P: DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect Prev. 1997;21(5):391-405. [PubMed:9307842]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...

Components:
References
  1. Holt A, Sharman DF, Callingham BA, Kettler R: Characteristics of procarbazine as an inhibitor in-vitro of rat semicarbazide-sensitive amine oxidase. J Pharm Pharmacol. 1992 Jun;44(6):487-93. [PubMed:1359073]
  2. Kraft SL, Baker NM, Carpenter J, Bostwick JR: Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity. Psychooncology. 2014 Jan;23(1):108-13. doi: 10.1002/pon.3378. Epub 2013 Aug 29. [PubMed:24038727]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:57